Ashurst joins legal line-up as Japan's Takeda seals £46bn takeover of Shire

Takeda Pharma offers $62 billion in takeover of Britain's Shire

Adderall maker Shire agrees £46bn takeover by Takeda

Takeda Pharmaceutical agreed to buy London-listed Shire for £45.3 billion ($61.50 billion) on Tuesday, marking the biggest deal yet in a wave of transactions sweeping the drugs industry.

Takeda will pay $66.56 per Shire share: $30.33 in cash, with the rest in the form of 0.839 of a new Takeda share.

Takeda and Shire shareholders will each own about half of the combined company.

"Shire's highly complementary product portfolio and pipeline, as well as experienced employees, will accelerate our transformation for a stronger Takeda", said Takeda President and CEO Christophe Weber in a statement.

To help fund the cash portion of the deal, Takeda said it had secured a bridging loan facility of US$31 billion with JPMorgan Chase Bank, Sumitomo Mitsui Banking Corp and MUFG Bank, among others.

Manchester City defender Vincent Kompany: 'I'm hungrier than ever'
Pep Guardiola was thrown in the air by his squad. "It wasn't a stolen point, it was a deserved point. We can not rely on anybody, we only have to trust ourselves".

Shire's shares, which had been trading about 10 pounds below the value of Takeda's offer, traded 4 percent higher at just over 40 pounds, still well under the agreed price and indicating that shareholders still have reservations.

On May 8, Japanese pharmaceutical giant Takeda announced it had finally come to an agreement to acquire Dublin-based drug maker Shire.

Takeda confirmed its pursuit of Shire in late March.

Takeda, founded in Osaka in 1781, wants Shire, a specialist in the treatment of rare conditions, to help it expand globally - especially in the USA - as it faces down the prospect of weaker drug prices in its home market. Takeda is valued at about $34 billion and makes nearly half of its sales in Asia, and about a third in the U.S. Among its top sellers are Entyvio, used to treat ulcerative colitis, and cancer drug Leuprorelin.

Takeda expects the merged firms will achieve cost-savings of at least US$1.4bn/y.

5 rebels, 5 civilians killed by Indian security forces
Hundreds of demonstrators tried to reach the site of the standoff and threw rocks at troops in a bid to help the trapped fighters. Also, in Siachen glacier in northern Kashmir, Indian and Pakistani troops have fought intermittently since 1984.

Susan Kilsby, the chairwoman of Shire, said: "Over the last 30 years, Shire has become the global leader in treating rare diseases".

Tokyo-listed Takeda's shares, however, climbed nearly four per cent to ¥4,638 (£31.50). Takeda's largest previous purchase was a US$13.7 billion takeover of Nycomed in 2011.

Takeda has been conducting due diligence for the past two weeks, but Shire had rejected its offer four times on price disagreement and also because it wanted more in cash and less in stock. Last year, the company expanded its footprint in the U.S. oncology market with the US$4.7 billion purchase of Ariad Pharmaceuticals.

Takeda said it would maintain its global headquarters in Japan and evaluate consolidating Shire's operations into Takeda's in the Boston area, Switzerland and Singapore.

Ohio State QB Joe Burrow Announces Plans To Transfer
Ohio State has all kinds of skill-position toys for Haskins to play around with assuming he does win the starting job this summer. After Burrow announced his decision to leave the Buckeyes, new Florida receiver Van Jefferson responded.

Latest News